Nuances in Efficacy, MACE Risk Revealed Between JAKi, TNFi

Three studies provide more data on risk for major adverse cardiovascular events with JAK inhibitors vs TNF inhibitors, as well as their efficacy in patients with different levels of risk.
Medscape Medical News

source https://www.medscape.com/viewarticle/992879?src=rss

Comments

Popular posts from this blog

New AAFP practice guideline sets blood pressure targets for adults with hypertension

RA and RA-ILD Linked to Higher Lung Cancer Risk

A Large Multicenter Prospective Study of Community-Onset Healthcare Associated Bacteremic Urinary Tract Infections in the Era of Multidrug Resistance: Even Worse than Hospital Acquired Infections?